title: Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
abstract: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor-based incretin therapy intended for the treatment of type 2 diabetes mellitus (T2DM), has not been linked to adverse effects on the pancreas in prospective clinical trials or in nonclinical toxicology studies. To further assess potential pancreatic effects, sitagliptin was studied in the male Zucker diabetic fatty (ZDF) rat model of T2DM. Following 3 months of oral dosing with vehicle, or sitagliptin at doses 3- to 19-fold above the clinically therapeutic plasma concentration, which increased active plasma glucagon-like peptide-1 levels up to approximately 3-fold, or following 3 months of oral dosing with metformin, a non-incretin-based reference T2DM treatment, the pancreas of male ZDF rats was evaluated using qualitative and quantitative histopathology techniques. In the quantitative evaluation, proliferative index was calculated in exocrine pancreatic ducts and ductules using computer-based image analysis on sections stained by immunohistochemistry for cytokeratin (a cytoplasmic epithelial cell marker) and Ki-67 (a nuclear marker of recent cell division). Relative to controls, sitagliptin treatment did not alter disease progression based on detailed clinical signs and clinical pathology assessments. Sitagliptin treatment did not result in pancreatitis or any adverse effect on the pancreas based on a qualitative histopathology evaluation. Proliferative index did not increase with sitagliptin treatment based on quantitative assessment of more than 5000 sections of pancreas, where control group means ranged from 0.698-0.845% and sitagliptin-treated group means ranged from 0.679-0.701% (P = .874). Metformin treatment was similarly evaluated and found not to have adverse effects on pancreas.
authors.affiliation: Merck & Co, Inc, Whitehouse Station, New Jersey.
authors.forename: Thomas
authors.initials: T
authors.lastname: Forest
authors.forename: Daniel
authors.initials: D
authors.lastname: Holder
authors.forename: Adam
authors.initials: A
authors.lastname: Smith
authors.forename: Caron
authors.initials: C
authors.lastname: Cunningham
authors.forename: Xiaorui
authors.initials: X
authors.lastname: Yao
authors.forename: Markus
authors.initials: M
authors.lastname: Dey
authors.forename: Clay
authors.initials: C
authors.lastname: Frederick
authors.forename: Srinivasa
authors.initials: S
authors.lastname: Prahalada
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight; D049109:Cell Proliferation; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D004195:Disease Models, Animal; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007633:Keratins / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000008:administration & dosage; D046790:Pancreas, Exocrine / Q000187:drug effects* / Q000473:pathology*; D011719:Pyrazines / Q000008:administration & dosage; D051381:Rats; D011924:Rats, Zucker; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D019394:Ki-67 Antigen; D011719:Pyrazines; D014230:Triazoles; D007633:Keratins; D008687:Metformin; D000068900:Sitagliptin Phosphate